Results 131 to 140 of about 5,019 (231)

A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy. [PDF]

J Nanobiotechnology
Zhu Z, Li J, Lu Q, Zeng W, Yu Z, Liu N, Zhang Z, Wang Z, Yang N, Chen Y, Lu H, Xu L, Nie C, Li H, Tong A.   +14 more
europepmc   +1 more source

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer. [PDF]

Mol Ther Oncolytics, 2023
Liu S, Li F, Deng L, Ma Q, Lu W, Zhao Z, Liu H, Zhou Y, Hu M, Wang H, Yan Y, Zhao M, Zhang H, Du M.   +13 more
europepmc   +1 more source

Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia. [PDF]

Blood Adv
Liegel J, Stroopinsky D, Cheloni G, Karagkouni D, Nahas M, Ma Y, Torres D, Saldarriaga I, Wang S, Arruda de Amaral A, Ploumakis A, Clohessy J, Abirached J, Bisharat L, Fraenkel P, Yildirim O, Bonnevaux H, Guerif S, Rallis K, Chedid G, Kufe D, Vlachos IS, Avigan D, Rosenblatt J.   +23 more
europepmc   +1 more source

Unmasking a Composite Lymphoma: Follicular Lymphoma Emerging After Bispecific Antibody Treatment of Marginal Zone Lymphoma

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Composite indolent B‐cell lymphomas may remain unrecognized when one component dominates the clinical presentation. Apparent relapse after therapy may, therefore, represent the emergence of a biologically distinct lymphoma rather than the recurrence of the original disease.
Angel Luis Orosco‐Ttamina, Jiehao Zhou, Juliana Biondo, Farah Hossain, David Viswanatha, Patricia T. Greipp, Natasha Lewis, Javier Munoz   +7 more
wiley   +1 more source

Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager. [PDF]

Mol Ther Oncol
Choi MJ, So EY, Akosman B, Lee YE, Raufi AG, Reginato AM, Chen CC, Lawler SE, Wong ET, Liang OD.   +9 more
europepmc   +1 more source

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy. [PDF]

Signal Transduct Target Ther, 2023
Yang XM, Lin XD, Shi W, Xie SX, Huang XN, Yin SH, Jiang XB, Hammock BD, Xu ZP, Lu XL.   +9 more
europepmc   +1 more source

Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance

MedComm, Volume 7, Issue 8, August 2026.
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar, Manisha Dagar, Ashna Gupta, Anju Surendranath, Suraja Kumar Das, Mohd Umar Rehmani, Mukesh Tanwar, Sameer Mirza, Muzafar A. Macha, Ammira S. Al‐Shabeeb Akil, Shahab Uddin, Mayank Singh, Ajaz A. Bhat   +12 more
wiley   +1 more source

A KRAS^G12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [PDF]

Mol Ther Oncol
Huynh N, Nguyen TT, Bui NT, Nguyen HN, Nguyen CT.   +4 more
europepmc   +1 more source

Metabolic Regulation of Macrophages in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Extracellular metabolites drive metabolic rewiring of glucose, lipid, and amino acid pathways in macrophages, steering their polarization toward pro‐ or anti‐inflammatory phenotypes and shaping a wide range of disease processes. Macrophages from different tissues display distinct metabolic signatures, and therapeutic strategies that target these ...
Shan Huang, Yu Zhang, Jiali Min, Jiahui Yang, Yuchen Li, Hao Zhang, Shanshan Liu   +6 more
wiley   +1 more source

Safety and Practicalities of Bispecific T-Cell Engager Administration in a District General Hospital Setting. [PDF]

EJHaem
Lau B, Gabrie S, Hobbs P, Newman J, Elzein A, Sargant N, Cowley A, Nikolova A, Flanagan C, Burt L, Saddleton M, Evans C, Street T, Mahbak H, Lazaro A, Grace R, Jones JR.   +16 more
europepmc   +1 more source